MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the Life Science business sector has signed an agreement with biotechnology company Innovative Biotech (IB) to design the manufacturing process for the first vaccine production facility in Nigeria.
“We are committed to expanding access to life-saving and life-enhancing therapies to patients across the world and this collaboration is a testament to that commitment,” said Andrew Bulpin, Head of Process Solutions, Life Science business sector. “We are proud to provide the technical support and expertise that could help enable the first vaccine facility in Nigeria and localize vaccine development in the West Africa region.”
This collaboration is part of the West African pandemic readiness program, which aims to localize vaccine development in the African nations. The first phase of this integrated partnership focuses on designing the fill and finish facility, incorporating Mobius® single-use technology offered by the Life Science business sector, while the second phase will focus on enabling continuous manufacturing.
“By leveraging facility design expertise of the Life Science business sector, we’ll be able to build the first vaccine production facility in Nigeria and manufacture high-quality and affordable vaccines locally,” said Simon Agwale, CEO of Innovative Biotech.
Innovative Biotech’s licensor, TechnoVax, is developing a virus-like-particle (VLP)-based vaccine to target variants of Covid-19. Provisional results from the preclinical studies of the VLP-based vaccine have shown promise for virus neutralization. Technovax is a 2019 recipient of MilliporeSigma’s Advance Biotech Grant for developing a virus-like particle platform that facilitates the development and production of a range of vaccines targeting the prevention of respiratory diseases, hemorrhagic fevers, immunodeficiency and cancers.
Social Plugin